MEDISTIM ASA financials
MEDISTIM ASA
5967007LIEEXZXJOX483 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | NOK 556.2M | NOK 521.1M |
| Other income | NOK 6.4M | NOK 5.3M |
| Employee benefits expense | NOK 185.1M | NOK 162.6M |
| Depreciation & amortisation | NOK 24.5M | NOK 23.7M |
| Operating profit (EBIT) | NOK 131.1M | NOK 131.4M |
| Net finance income / (cost) | NOK 3.2M | NOK 3.8M |
| Finance costs | NOK 8.3M | NOK 13.4M |
| Profit before tax | NOK 134.2M | NOK 135.2M |
| Income tax expense | NOK 30.4M | NOK 31.4M |
| Profit for the year | NOK 103.8M | NOK 103.8M |
| Total comprehensive income | NOK 120.0M | NOK 106.4M |
| Per share | ||
| Basic EPS | NOK 5.67 | NOK 5.68 |
| Diluted EPS | NOK 5.67 | NOK 5.67 |
| Free cash flow / share | NOK 7.48 | NOK 5.61 |
| Cash flow statement | ||
| Net cash from operating activities | NOK 143.1M | NOK 119.2M |
| Income taxes paid | NOK 28.4M | NOK 25.7M |
| Net cash from investing activities | -NOK 24.7M | -NOK 29.7M |
| Purchase of PP&E (capex) | NOK 6.1M | NOK 16.4M |
| Net cash from financing activities | -NOK 91.5M | -NOK 90.9M |
| Dividends paid | NOK 82.4M | NOK 82.2M |
| Lease liability payments | NOK 9.1M | NOK 8.7M |
| Balance sheet | ||
| Total assets | NOK 575.0M | NOK 505.7M |
| Non-current assets | NOK 145.8M | NOK 114.2M |
| Property, plant & equipment | NOK 73.2M | NOK 57.3M |
| Intangible assets & goodwill | NOK 59.3M | NOK 45.4M |
| Current assets | NOK 429.1M | NOK 391.6M |
| Inventories | NOK 160.5M | NOK 145.4M |
| Trade & other receivables | NOK 69.0M | NOK 74.3M |
| Cash & equivalents | NOK 179.2M | NOK 153.9M |
| Total equity | NOK 436.6M | NOK 397.9M |
| Non-current liabilities | NOK 31.0M | NOK 13.5M |
| Lease liabilities (non-current) | NOK 25.1M | NOK 9.3M |
| Current liabilities | NOK 107.4M | NOK 94.3M |
| Lease liabilities (current) | NOK 9.3M | NOK 8.4M |
| Derived metrics | ||
| Free cash flow | NOK 137.0M | NOK 102.8M |
| Operating margin | 23.6% | 25.2% |
| Net margin | 18.7% | 19.9% |
| Return on equity | 23.8% | 26.1% |
| Cash conversion ratio | 1.38× | 1.15× |
| Capex coverage | 23.58× | 7.27× |
| Other reported items | ||
| Additional Paidin Capital | NOK 25.8M | NOK 24.7M |
| Adjustments For Decrease Increase In Inventories | -NOK 15.1M | -NOK 31.1M |
| Adjustments For Decrease Increase In Trade Account Receivable | NOK 5.3M | NOK 27.4M |
| Adjustments For Depreciation and Amortisation Expense | NOK 24.5M | NOK 23.7M |
| Adjustments For Increase Decrease In Trade Account Payable | NOK 2.0M | NOK 613.0K |
| Adjustments For Sharebased Payments | NOK 1.1M | NOK 6.0M |
| Cash | NOK 171.3M | NOK 146.1M |
| Current Provisions | NOK 2.8M | NOK 988.0K |
| Current Tax Liabilities Current | NOK 27.4M | NOK 28.4M |
| Deferred Tax Assets | NOK 9.0M | NOK 5.1M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | NOK 6.00 | NOK 4.50 |
| Dividends Recognised As Distributions To Owners Per Share | NOK 4.50 | NOK 4.50 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -NOK 1.5M | NOK 2.7M |
| Equity and Liabilities | NOK 575.0M | NOK 505.7M |
| Finance Income | NOK 11.5M | NOK 17.1M |
| Increase Decrease In Cash and Cash Equivalents | NOK 25.3M | NOK 1.2M |
| Increase Decrease Through Sharebased Payment Transactions | NOK 1.1M | NOK 6.0M |
| Issued Capital | NOK 4.6M | NOK 4.6M |
| Liabilities | NOK 138.4M | NOK 107.8M |
| Noncurrent Deferred Income Including Noncurrent Contract Liabilities | NOK 5.9M | NOK 4.2M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | NOK 16.2M | NOK 2.6M |
| Other Current Liabilities | NOK 50.1M | NOK 31.4M |
| Other Current Receivables | NOK 20.4M | NOK 18.0M |
| Other Expense By Nature | NOK 108.2M | NOK 96.4M |
| Other Noncurrent Receivables | NOK 4.3M | NOK 6.3M |
| Other Reserves | NOK 35.6M | NOK 19.4M |
| Payments For Development Project Expenditure | NOK 18.6M | NOK 13.3M |
| Restricted Cash and Cash Equivalents | NOK 7.9M | NOK 7.8M |
| Retained Earnings | NOK 328.8M | NOK 307.4M |
| Revenue and Operating Income | NOK 562.6M | NOK 526.4M |
| Share Premium | NOK 41.9M | NOK 41.9M |
| Trade and Other Current Payables To Trade Suppliers | NOK 17.7M | NOK 25.1M |
| Treasury Shares | NOK 6.0K | NOK 13.0K |
Every line item above is a fact tagged in MEDISTIM ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (NOK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.